In addition to my prior post, and very importantly, the new 120mcg cohort extension study will provide an opportunity to evaluate whether time intervals between doses can be extended upon. If successful, the benefit will work in favour of both clinicians and patients alike. (Provided 120mcg is proven safe).
I believe the aspect driving the increased dose idea relates to our platform technology and it's precision to target specific genes and deliver a relatively high dose within the targeted cell whilst the overall dose, (120mcg), may considered fairly low to other delivery technologies. In other words PYC are looking to differentiate the technology of their platform in a very meaningful way for the benefit of all concerned.
They are going for GOLD!!
PYC Price at posting:
$1.21 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)